This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

The Lucy Wortham James Clinical Research Award

Sarah S. Donaldson, MD

Arch Surg. 1989;124(9):1015-1020.

Abstract
• Approximately two thirds of children with rhabdomyosarcoma will be cured of their tumor and become long-term survivors. Multidisciplinary care has brought about improvements in survival. Yet our therapies of today are suboptimal in many situations and demand intense effort toward improving cure rates and quality of life. Rhabdomyosarcoma is a complex childhood malignancy with differing anatomic sites of presentation and varying histologic subtypes, each presenting with unique patterns of growth, making it inappropriate to consider the disease a single entity. Avenues of future research involve cytogenetic and molecular genetic investigations that will aid in diagnosis and screening and, it is hoped, guide clinicians to more specific therapy.

(Arch Surg. 1989;124:1015-1020)

Author Affiliations
From the Department of Radiation Oncology, Stanford (Calif) University School of Medicine.

Footnotes
Accepted for publication April 22, 1989.

Presented at the Annual Meeting of the Society of Surgical Oncology, New Orleans, La, May 23, 1988.

Reprint requests to Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 (Dr Donaldson).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pediatric Head and Neck Rhabdomyosarcoma
MacArthur et al.
CLIN PEDIATR 1992;31:66-70.
ABSTRACT